[10]Liefaard MC, van der Voort A, van Seijen M, et al. Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade. NPJ Breast Cancer. 2024;10(1):29. [...
近日,山东大学材料学院蒋妍彦团队在Advanced Science(IF=16.8 一区)杂志上发表了题为:“A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer.”的文章,研究团队开发了一个纳米治疗平台,结合了双金属金银空心纳米壳、吡咯替尼和赫赛汀,实现了多...
[26]Tolaney SM,et al.A phase II randomized study to compare abemaciclib plus trastuzumab with or without fulvestrant to standard of care chemotherapy plus trastuzumab in hormone receptor positive,HER2-positive advanced breast cancer(monarcHER):American Society of Clinical Oncology;2017. [27]Ciruelos E...
[8]He X,Ji J,Tian M,et al.Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1,Node-Negative HER2-Positive Breast Cancer.Clin Cancer Res.2019 Dec 15;25(24):7388-7395. [9]von Minckwitz G,Huang CS,Mano MS,et al.Trastuzumab Emtansine for R...
the peony phase 3 randomized clinical trial. jama oncol. 2020;6(3):e193692. doi:10.1001/jamaoncol.2019.3692 3.hurvitz sa, martin m, symmans wf, et al. neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab...
11. Varadan, V. et al. Immune signatures following single dose trastuzumab predict pathologic response to preoperative trastuzumab and chemotherapy in HER2-positive early breast cancer.Clin. Cancer Res. 22, 3249–3259 (2016). 12. Triulzi, T. et al. HER2 signaling regulates the tumor immunemicro...
1. Hurvitz S A, Martin M, Symmans W F, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial[J]. The Lancet Oncology, 2018, 19(1...
[1] Edith, et al., Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 2014. 32(33). ...
free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.[J]. European journal of cancer (Oxford, England : 1990),2022,...
[1] Shi Q, Xuhong J, Luo T, et al. PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. Br J Cancer. 2023;128(1):121-129. ...